Previous 10 | Next 10 |
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton Potential first-in-class approach focused on HGF modulation for treatme...
VACAVILLE, CA / ACCESSWIRE / January 2, 2024 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNR) ("Athena" or the "Company") is pleased to announce that it has closed its previously announced acquisition (the "Acquisition") of 10,000,000 common shares in the capital of Nubian Resources Ltd., a comp...
2024-01-02 10:27:51 ET More on Athira Pharma Seeking Alpha’s Quant Rating on Athira Pharma Historical earnings data for Athira Pharma Financial information for Athira Pharma For further details see: Athira Pharma 10% owner Perceptive Advisors discl...
2023-12-12 08:39:32 ET Losers: Achieve Life Sciences ( ACHV ) -24% announces participation at upcoming investor conferences. Clearmind Medicine CMND -13% files for $50M mixed shelf . Oracle Corp. ORCL -10% after Q2 earnings release . Acurx Pharmaceu...
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases Cognitive measures in the 40 mg dose group bolster confidence in ongoing Phase 2/...
Objective is to Refine 2024 Drill Targets RENO, NV / ACCESSWIRE / December 12, 2023 / Athena Gold Corporation (OTCQB:AHNR)(CSE:ATHA) (" Athena " or the " Company ") is pleased to announce it has contracted with Zonge International, Inc. to perform an IP/Resistivity (the " Survey ") at its 10...
NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December 6-7, 2023. The presentation schedule is su...
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Si...
BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that a symposium presentation highlighting data fr...
BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data supporting the potential therapeuti...
News, Short Squeeze, Breakout and More Instantly...
Athira Pharma Inc. Company Name:
ATHA Stock Symbol:
NASDAQ Market:
BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused o...
BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Ch...
BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting th...